Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

Similar articles for PubMed (Select 24338782)

1.

Microsphere priming facilitates induction of potent therapeutic T-cell immune responses against autochthonous liver cancers.

Brinkhoff B, Ostroumov D, Heemcke J, Woller N, Gürlevik E, Manns MP, Longerich T, Zender L, Harty JT, Kubicka S, Kühnel F, Wirth TC.

Eur J Immunol. 2014 Apr;44(4):1213-24. doi: 10.1002/eji.201343794. Epub 2014 Jan 16.

PMID:
24338782
2.

Tumor eradication by immunotherapy with biodegradable PLGA microspheres--an alternative to incomplete Freund's adjuvant.

Mueller M, Schlosser E, Gander B, Groettrup M.

Int J Cancer. 2011 Jul 15;129(2):407-16. doi: 10.1002/ijc.25914. Epub 2011 Mar 28.

PMID:
21207410
3.

Exploiting cross-priming to generate protective CD8 T-cell immunity rapidly.

Pham NL, Pewe LL, Fleenor CJ, Langlois RA, Legge KL, Badovinac VP, Harty JT.

Proc Natl Acad Sci U S A. 2010 Jul 6;107(27):12198-203. doi: 10.1073/pnas.1004661107. Epub 2010 Jun 21.

4.

Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma.

Goforth R, Salem AK, Zhu X, Miles S, Zhang XQ, Lee JH, Sandler AD.

Cancer Immunol Immunother. 2009 Apr;58(4):517-30. doi: 10.1007/s00262-008-0574-6. Epub 2008 Aug 22.

PMID:
18719913
5.

CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.

Rosalia RA, Cruz LJ, van Duikeren S, Tromp AT, Silva AL, Jiskoot W, de Gruijl T, Löwik C, Oostendorp J, van der Burg SH, Ossendorp F.

Biomaterials. 2015 Feb;40:88-97. doi: 10.1016/j.biomaterials.2014.10.053. Epub 2014 Nov 26.

PMID:
25465442
6.

Poly(D,L-lactic-co-glycolic acid) microsphere delivery of adenovirus for vaccination.

Wang D, Molavi O, Lutsiak ME, Elamanchili P, Kwon GS, Samuel J.

J Pharm Pharm Sci. 2007;10(2):217-30.

7.

Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands.

Grossmann C, Tenbusch M, Nchinda G, Temchura V, Nabi G, Stone GW, Kornbluth RS, Uberla K.

BMC Immunol. 2009 Aug 3;10:43. doi: 10.1186/1471-2172-10-43.

8.

Booster vaccinations against cancer are critical in prophylactic but detrimental in therapeutic settings.

Ricupito A, Grioni M, Calcinotto A, Hess Michelini R, Longhi R, Mondino A, Bellone M.

Cancer Res. 2013 Jun 15;73(12):3545-54. doi: 10.1158/0008-5472.CAN-12-2449. Epub 2013 Mar 28.

9.

A therapeutic microparticle-based tumor lysate vaccine reduces spontaneous metastases in murine breast cancer.

Gross BP, Wongrakpanich A, Francis MB, Salem AK, Norian LA.

AAPS J. 2014 Nov;16(6):1194-203. doi: 10.1208/s12248-014-9662-z. Epub 2014 Sep 16.

PMID:
25224145
10.
11.

Conventional dendritic cells are required for the activation of helper-dependent CD8 T cell responses to a model antigen after cutaneous vaccination with lentiviral vectors.

Goold HD, Escors D, Conlan TJ, Chakraverty R, Bennett CL.

J Immunol. 2011 Apr 15;186(8):4565-72. doi: 10.4049/jimmunol.1002529. Epub 2011 Mar 9.

13.

Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.

Tatsumi T, Takehara T, Kanto T, Miyagi T, Kuzushita N, Sugimoto Y, Jinushi M, Kasahara A, Sasaki Y, Hori M, Hayashi N.

Cancer Res. 2001 Oct 15;61(20):7563-7.

14.

Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.

Grosenbach DW, Barrientos JC, Schlom J, Hodge JW.

Cancer Res. 2001 Jun 1;61(11):4497-505.

15.

Tumor-associated antigen expressing Listeria monocytogenes induces effective primary and memory T-cell responses against hepatic colorectal cancer metastases.

Olino K, Wada S, Edil BH, Pan X, Meckel K, Weber W, Slansky J, Tamada K, Lauer P, Brockstedt D, Pardoll D, Schulick R, Yoshimura K.

Ann Surg Oncol. 2012 Jul;19 Suppl 3:S597-607. doi: 10.1245/s10434-011-2037-0. Epub 2011 Oct 7.

PMID:
21979110
16.

Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity.

Hamdy S, Molavi O, Ma Z, Haddadi A, Alshamsan A, Gobti Z, Elhasi S, Samuel J, Lavasanifar A.

Vaccine. 2008 Sep 15;26(39):5046-57. doi: 10.1016/j.vaccine.2008.07.035. Epub 2008 Aug 3.

PMID:
18680779
17.

Efficient eradication of subcutaneous but not of autochthonous gastric tumors by adoptive T cell transfer in an SV40 T antigen mouse model.

Bourquin C, von der Borch P, Zoglmeier C, Anz D, Sandholzer N, Suhartha N, Wurzenberger C, Denzel A, Kammerer R, Zimmermann W, Endres S.

J Immunol. 2010 Aug 15;185(4):2580-8. doi: 10.4049/jimmunol.0903231. Epub 2010 Jul 19.

18.

Coencapsulation of tumor lysate and CpG-ODN in PLGA-microspheres enables successful immunotherapy of prostate carcinoma in TRAMP mice.

Mueller M, Reichardt W, Koerner J, Groettrup M.

J Control Release. 2012 Aug 20;162(1):159-66. doi: 10.1016/j.jconrel.2012.06.015. Epub 2012 Jun 15.

PMID:
22709589
19.

Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model.

Jia Y, Yin Y, Duan F, Fu H, Hu M, Gao Y, Pan Z, Jiao X.

Int J Mol Med. 2012 Dec;30(6):1335-42. doi: 10.3892/ijmm.2012.1136. Epub 2012 Sep 20.

PMID:
23027427
20.

Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.

Jasani B, Navabi H, Adams M.

Vaccine. 2009 May 26;27(25-26):3401-4. doi: 10.1016/j.vaccine.2009.01.071. Epub 2009 Feb 5.

PMID:
19200817
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk